Clinical utility of adjunctive retigabine in partial onset seizures in adults

In ~30% of epileptic patients, full seizure control is not possible, which is why the search for novel antiepileptic drugs continues. Retigabine exhibits a mechanism of action that is not shared by the available antiepileptic drugs. This antiepileptic enhances potassium currents via Kv7.2-7.3 channe...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutics and clinical risk management 2012-01, Vol.8 (default), p.7-14
Main Authors: Rejdak, Konrad, Luszczki, Jarogniew J, Błaszczyk, Barbara, Chwedorowicz, Roman, Czuczwar, Stanislaw J
Format: Article
Language:English
Subjects:
Anticonvulsants
antiepileptic drugs
Convulsions & seizures
Epilepsy
Evidence-based medicine
Review
seizure control
Seizures (Medicine)
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In ~30% of epileptic patients, full seizure control is not possible, which is why the search for novel antiepileptic drugs continues. Retigabine exhibits a mechanism of action that is not shared by the available antiepileptic drugs. This antiepileptic enhances potassium currents via Kv7.2-7.3 channels, which very likely results from destabilization of a closed conformation or stabilization of the open conformation of the channels. Generally, the pharmacokinetics of retigabine are linear and the drug undergoes glucuronidation and acetylation. Results from clinical trials indicate that, in the form of an add-on therapy, retigabine proves an effective drug in refractory epileptic patients. The major adverse effects of the add-on treatment are dizziness, somnolence, and fatigue. This epileptic drug is also considered for other conditions - neuropathic pain, affective disorders, stroke, or even Alzheimer's disease.
ISSN:1178-203X
1176-6336
1178-203X
DOI:10.2147/TCRM.S22605